SachdevPThomasMD

PubMed

• 24 citations
  A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer.
  Richard T. Lee, Kathleen E. Beekman, Maha Hussain, Nancy B. Davis, Joseph I. Clark
  Clinical Genitourinary Cancer. 2008-03-01
• 57 citations
  Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygen...
  Martin J. Edelman, Xiaofei Wang, Lydia Hodgson, Richard T. Cheney, Maria Q. Baggstrom
  Journal of Clinical Oncology. 2017-05-10
• 197 citations
  Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer
  Suresh S. Ramalingam, Michael L. Maitland, Paul Frankel, Athanassios Argiris, Marianna Koczywas
  Journal of Clinical Oncology. 2010-01-01

Journal Articles

• Carboplatin and Paclitaxel in Combination with Either Vorinostat or Placebo for First-Line Therapy of Advanced Non-Small Cell Lung Cancer.  
  Ramalingam SS, Maitland ML, Frankel P, Argirls AE, Koczywas M, Gitiltz B, Thomas S, Espinoza-Delgado I, Vokes EE, Gandara DR, Belani CP, JCO, 1/1/2010
• A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer.  
  Lee RT, Beekman KE, Hussain M, Davis NB, Clark JI, Thomas SP, Nichols KF, Stadler WM, Clin Genitourin Cancer, 3/1/2008
• "Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer and a Performance Status of 2".  
  Lilenbaum R, Axelrod R, Thomas S, Dowlati A, Seigel L, Albert D, Witt K, Botkin D, JCO, 2/20/2008
• "Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcitabine As Front-Line Therapy for Advanced Non-Small-Cell Lung Cancer".  
  Ma CX, Nair S, Thomas S, Mandrekar SJ, Nikcevich DA, Rowland KM, Fitch TR, Windschitl HE, Hillman SL, Schild SE, Jett JR, Obasaju C, Adjei AA; North Central Cancer Tre..., JCO, 9/1/2005
• "Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741".  
  Delaunoit T, Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Findlay BP, Thomas SP, Salim M, Schaefer PL, Stella PJ, Green E, Mailliard JA, Cancer, 11/15/2004
• "Genomic Organization and Refined Mapping of the Human Nuclear Corepressor 2 (NCOR2)/ Silencing Mediator of Retinoid and Thyroid Hormone Receptor (SMRT) Gene on Chromo...  
  Jiang Q, Galiegue-Zouitina S, Roumier C, Hildebrand MP, Thomas S, Coignet LJ, Cytogenet Cell Genet, 1/1/2001
• Join now to see all

Abstracts/Posters

• "A Phase I Trial of Adjuvant Radiochemotherapy Using Docetaxel for Resectable High Risk Squamous Cell Carcinoma (SCC) of the Head and Neck".
  Hofmeister C, Lau-Schwabe A, Petruzzelli G, Emami B, Thomas S, Clark JI, Lung Cancer
• "Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium".
  Campbell NP, Kunnavakkam R, Leighl N, Vincent MD, Gandara DR, Koczywas M, Gitlitz BJ, Agamah E, Thomas SP, Stadler WM, Vokes EE, Kindler HL, Lung Cancer, 10/1/2012
• "Connect MM: The multiple myeloma (MM) disease registry - Incidence of second primary malignancies (SPM)".
  Rifkin RM, Abonour R, Fonseca R, Gasparetto C, Mehta J, Narang M, Pashos CL, Thomas SP, Shah JJ, Terebelo HR, Toomey K, Minton N, Srinivasan S, Street T, Sullivan K, D..., J Clin Oncol, 5/20/2012
• "A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) and vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic panc...
  Catenacci DVT, Bahary N, Edelman MJ, Nattam SR, Marsh R, Kaubisch A, Wallace JA, Cohen DJ, Stiff PJ, Sleckman BG, Thomas SP, Lenz HJ, Henderson L, Zagaya C, Vannier M,..., J Clin Oncol, 5/20/2012
• "N0321: A phase II study of bortezomib, paclitaxel, carboplatin (CBCDA), and radiotherapy (RT) for locally advanced nonsmall cell lung cancer (NSCLC)".
  Schild SE, Foster NR, Molina JR, Dy GK, Rowland KM, Sarkaria JN, Thomas SP, Northfelt DW, Kugler JW, Adjei AA, J Clin Oncol, 5/20/2012
• "N0821: A phase II first-line study of a combination of pemetrexed (P), carboplatin ©, and bevacizumab (B) in elderly patients with good performance status (PS < 2)".
  Dy GK, Molina JR, Qi Y, Ansari RH, Thomas SP, Ross HJ, Meyers JP, Adjei A, Mandrekar SJ, Adjei AA, J Clin Oncol, 5/20/2012
• "Phase I trial of temsirolimus and lenalidomide in patients with rel/ref lymphomas".
  Smith SM, Cohen KS, Kline JP, Zavala JD, Conner K, Thomas SP, Lesho P, Doyle LA, Stadler WM, Karrison T, Kimball AS, J Clin Oncol, 5/20/2012
• "MAVERICC: A randomized phase II study of mFOLFOX6-bevacizumab (BV) versus FOLFIRI-BV with prospective biomarker stratification in previously untreated metastatic co...
  Thomas SP, Badarinath S, Greenberg RH, Huh SY, Sivarajan KM, Feng S, Scherer S, Curry CL, Langer C, Lenz HJ, J Clin Oncol, 5/20/2012
• "Cediranib (C) in patients (pts) with malignant mesothelioma (MM): A phase II trial of The University of Chicago Phase II Consortium".
  Campbell NP, Kunnavakkam R, Leighl NB, Vincent MD, Gandara DR, Koczywas M, Gitlitz BJ, Agamah ES, Thomas SP, Stadler WM, Vokes EE, Kindler HL, J Clin Oncol, 1/1/2011
• "30 Day Mortality of Right Lobectomy Versus Right Pneumonectomy for Curative Resection of Non-Small Cell Lung Cancer".
  Thomas SP, Mueller D, Anderson R, Wang H, Follies S, Illinois CancerCare, Peoria, IL; Heart Care Midwest, Peoria, IL; UICOMP, Department of Medicine, Peoria, IL; OSF S..., Chicago Thoracic Oncology Symposium, 12/9/2010
• "N0321: A phase I study of bortezomib, paclitaxel, carboplatin (CBDCA), and radiotherapy (RT) for locally advanced non-small cell lung cancer (NSCLC)". (Poster Discuss...
  Schild SE, Molina JR, Dy GK, Rowland KM, Sakaria JN, Thomas SP, Northfelt DW, Kugler JW, Foster NR, Adjei AA, J Clin Oncol, 1/1/2010
• "Placebo-Controlled Trial to Determine the Effectiveness of a Ure/Lactic Acid-Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome...
  Wolf SL, Qin R, Menson SP, Rowland KM, Thomas, S, Delaune R, Christian D Pajon ER, Satele DV, Berenberg JL, Loprinzi CL, J Clin Oncol, 1/1/2010
• "The prognostic significance of immunohistochemical (IHC) staining of the sentinal lymph node (SNL) in breast cancer patients".
  Thomas SP, Sood N, Wang H, Williams N, Graumlich JF, J Clin Oncol 28, 1/1/2010
• "Incidence of febrile neutropenia in lymphoma patients receiving CHOP with Day 1 or 2 pegfilgrastim".
  Woods MA, Lopez T, Thomas SP, Harwood H, Kettler SM, J Clin Oncol 28, 1/1/2010
• "Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML)".
  Odenike O, Curran E, Iyengar N, Popplewell L, Kirschbaum M, Erba HP, Green M, Poire X, Ihonor P, Diaz-Flores E, Shannon K, Atallah E, Wade JL, Perdekamp M, Nattam S, T..., Proc 51st Annu Meet Am Soc Hema, 1/1/2009
• "Incidence of febrile neutropenia (FN) with pegfilgatim (PF) on day of chemotherapy (D1) versus 24-72 hours later (D2)".
  Kumar P, Ingle AM, Miller S, Woods M, Thomas SP, Children’s JCO, 1/1/2009
• "N02C1: A phase III randomized, placebocontrolled, double-blind trial of risedronate for prevention of bone loss in premenopausal women undergoing adjuvant chemotherap...
  Hines SL, Mincey BA, Sloa JA, Thomas SP, Chottiner EG, Loprinz CL, Atherton PJ, Carlson MD, Salim M, Perez EA, Proc Annu Meet Am Soc Clin Oncol, 1/1/2008
• "Impact of number of lymph nodes (LN) examined at the time of surgical resection (Sx) on the survival of stage IA non-small cell lung cancer (NSCLC) patients (pts)."
  Ingle M, Kumar P, Griggs MM, Erangey CA, Thomas SP, Proc Annu Meet Am Soc Clin Oncol, 1/1/2008
• "University of Chicago Consortium phase II study of ispinesib (SB-715992) in patients (pts) with advanced renal cell carcinoma (RCC)".
  Beekman KW, Dunn R, Colevas D, Davis N, Clark J, Agamah E, Thomas S, Nichols K, Redman B, Stadler W, Proc Annu Meet Am Soc Clin Oncol Part I, 1/1/2007
• "ECOG 1503: A Phase II Trial of Triapine with Gemcitabine as 2nd Line Treatment of Non-Small Cell Lung Cancer".
  Traynor AM, Levy DE, Bayer GK, Tate JM, Thomas SP, Maruczarak MA, Graham DL, Kolesar JM, Schiller JH, Proc Annu Meet Am Soc Clin Oncol, 1/1/2006
• Randomized Phase II Trial of Single Agent Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer and Performance Status of 2.
  Lilebaum R, Axerold R, Thomas S, Dowlati A, Seigel L, Albert D, Van Duym C, Bodkin D, Proc Ann Meet Am Soc Clin Oncol, 1/1/2006
• "Phase II Study of Bortezomib in Advanced or Metastatic Urothelial Cancer: A Trial of the Princess Margaret Hospital Phase II Consortium".
  Sridhar SS, Stadler W, Le E, Hedley D, Pond G, Wright J, Vokes E, Thomas S, Moore M, Proc Ann Meet Am Soc Clin Oncol, 1/1/2005
• "CD10 Detection by Flow Cytometry as a Prognostic Marker in de Novo Diffuse Large B-Cell Lymphoma".
  Siebert JD, Weeks LM, Sun J, Knost JA, Fishkin PAS, Thomas SP, Kugler JW, Am J Clin Path, 1/1/2002
• Join now to see all

Lectures

• "MAVERICC: A randomized phase II study of mFOLFOX6-bevacizumab (BV) versus FOLFIRI-BV with prospective biomarker stratification in previously untreated metastatic co... 
  2012 ASCO Annual Meeting - 1/1/2012
• "Phase I trial of temsirolimus and lenalidomide in patients with rel/ref lymphomas". 
  2012 ASCO Annual Meeting - 1/1/2012
• "N0821: A phase II first-line study of a combination of pemetrexed (P), carboplatin ©, and bevacizumab (B) in elderly patients with good performance status (PS < 2)". 
  2012 ASCO Annual Meeting - 1/1/2012
• "N0321: A phase II study of bortezomib, paclitaxel, carboplatin (CBCDA), and radiotherapy (RT) for locally advanced nonsmall cell lung cancer (NSCLC)". 
  2012 ASCO Annual Meeting - 1/1/2012
• "A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) and vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic panc... 
  2012 ASCO Annual Meeting - 1/1/2012
• "Connect MM: The multiple myeloma (MM) disease registry - Incidence of second primary malignancies (SPM)". 
  2012 ASCO Annual Meeting - 1/1/2012
• "Cediranib (C) in patients (pts) with malignant mesothelioma (MM): A phase II trial of The University of Chicago Phase II Consortium". 
  2011 ASCO Annual Meeting - 1/1/2011
• "Incidence of febrile neutropenia in lymphoma patients receiving CHOP with Day 1 or 2 pegfilgrastim". 
  2010 ASCO Annual Meeting - 1/1/2010
• "The prognostic significance of immunohistochemical (IHC) staining of the sentinal lymph node (SNL) in breast cancer patients". 
  2010 ASCO Annual Meeting - 1/1/2010
• "Placebo-Controlled Trial to Determine the Effectiveness of a Ure/Lactic Acid-Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome... 
  2010 ASCO Annual Meeting - 1/1/2010
• "Incidence of febrile neutropenia (FN) with pegfilgatim (PF) on day of chemotherapy (D1) versus 24-72 hours later (D2)". 
  Illinois CancerCare, Peoria, IL - 1/1/2009
• Join now to see all